AAPL   322.95 (-0.67%)
MSFT   183.22 (-1.15%)
FB   227.00 (-1.37%)
GOOGL   1,417.73 (-1.50%)
NVDA   351.24 (+0.13%)
BABA   218.74 (+0.06%)
MU   50.83 (+3.90%)
GE   7.46 (+1.36%)
TSLA   877.80 (-0.58%)
AMD   52.49 (-0.46%)
T   31.57 (+0.16%)
ACB   14.17 (-0.91%)
F   6.33 (+1.93%)
GILD   76.23 (+2.46%)
NFLX   417.60 (-1.04%)
BAC   26.19 (+0.92%)
BA   183.96 (+6.24%)
AAPL   322.95 (-0.67%)
MSFT   183.22 (-1.15%)
FB   227.00 (-1.37%)
GOOGL   1,417.73 (-1.50%)
NVDA   351.24 (+0.13%)
BABA   218.74 (+0.06%)
MU   50.83 (+3.90%)
GE   7.46 (+1.36%)
TSLA   877.80 (-0.58%)
AMD   52.49 (-0.46%)
T   31.57 (+0.16%)
ACB   14.17 (-0.91%)
F   6.33 (+1.93%)
GILD   76.23 (+2.46%)
NFLX   417.60 (-1.04%)
BAC   26.19 (+0.92%)
BA   183.96 (+6.24%)
AAPL   322.95 (-0.67%)
MSFT   183.22 (-1.15%)
FB   227.00 (-1.37%)
GOOGL   1,417.73 (-1.50%)
NVDA   351.24 (+0.13%)
BABA   218.74 (+0.06%)
MU   50.83 (+3.90%)
GE   7.46 (+1.36%)
TSLA   877.80 (-0.58%)
AMD   52.49 (-0.46%)
T   31.57 (+0.16%)
ACB   14.17 (-0.91%)
F   6.33 (+1.93%)
GILD   76.23 (+2.46%)
NFLX   417.60 (-1.04%)
BAC   26.19 (+0.92%)
BA   183.96 (+6.24%)
AAPL   322.95 (-0.67%)
MSFT   183.22 (-1.15%)
FB   227.00 (-1.37%)
GOOGL   1,417.73 (-1.50%)
NVDA   351.24 (+0.13%)
BABA   218.74 (+0.06%)
MU   50.83 (+3.90%)
GE   7.46 (+1.36%)
TSLA   877.80 (-0.58%)
AMD   52.49 (-0.46%)
T   31.57 (+0.16%)
ACB   14.17 (-0.91%)
F   6.33 (+1.93%)
GILD   76.23 (+2.46%)
NFLX   417.60 (-1.04%)
BAC   26.19 (+0.92%)
BA   183.96 (+6.24%)
Log in

OTCMKTS:RNUGFReNeuron Group Stock Price, Forecast & News

$1.75
0.00 (0.00 %)
(As of 06/4/2020 11:21 AM ET)
Add
Compare
Today's Range
$1.75
Now: $1.75
$1.75
50-Day Range
$1.50
MA: $1.79
$1.98
52-Week Range
$0.95
Now: $1.75
$3.29
VolumeN/A
Average Volume318 shs
Market Capitalization$55.70 million
P/E RatioN/A
Dividend YieldN/A
Beta-25.95
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Read More
ReNeuron Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RNUGF
Previous SymbolNASDAQ:RNUGF
CUSIPN/A
CIKN/A
Phone44-0-20-3819-8400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60,000.00

Profitability

Miscellaneous

Employees62
Market Cap$55.70 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RNUGF News and Ratings via Email

Sign-up to receive the latest news and ratings for RNUGF and its competitors with MarketBeat's FREE daily newsletter.

ReNeuron Group (OTCMKTS:RNUGF) Frequently Asked Questions

How has ReNeuron Group's stock been impacted by COVID-19 (Coronavirus)?

ReNeuron Group's stock was trading at $1.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RNUGF stock has increased by 0.0% and is now trading at $1.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ReNeuron Group?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ReNeuron Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ReNeuron Group.

What price target have analysts set for RNUGF?

1 Wall Street analysts have issued 1-year price targets for ReNeuron Group's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate ReNeuron Group's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 242.9% from the stock's current price. View analysts' price targets for ReNeuron Group.

Has ReNeuron Group been receiving favorable news coverage?

News coverage about RNUGF stock has been trending somewhat positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ReNeuron Group earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutReNeuron Group.

Who are some of ReNeuron Group's key competitors?

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the following people:
  • Mr. Olav Hellebø, CEO & Director (Age 54)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
  • Dr. Randolph Corteling, Head of Research
  • Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the OTCMKTS under the ticker symbol "RNUGF."

How do I buy shares of ReNeuron Group?

Shares of RNUGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ReNeuron Group's stock price today?

One share of RNUGF stock can currently be purchased for approximately $1.75.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of $55.70 million and generates $60,000.00 in revenue each year. ReNeuron Group employs 62 workers across the globe.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is www.reneuron.com.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY. The company can be reached via phone at 44-0-20-3819-8400.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.